ReviewJSES reviews, reports, and techniques2026
Rotator cuff repair and biologic augmentation-what do we know?
Review in JSES reviews, reports, and techniques, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite advancements in rotator cuff repair (RCR) techniques, failure of tendon healing remains common. In recent years, there has been an increasing body of work assessing the healing environment of the injured rotator cuff and exploring which adjuncts may be suitable to augment repairs. Methods: In this review, we summarize the best available literature regarding the biology of rotator cuff healing and the use of platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), scaffold-, and graft-based augmentations to RCR to guide the treating clinician. Results: Proposed treatment modalities range from injection-based augmentation such as PRP and BMAC to scaffold and graft-based augmentations at the time of RCR. Conclusion: The field of biologic augmentation for RCR is rapidly evolving and has demonstrated substantial potential in improving structural integrity and healing rates. PRP, BMAC, as well as scaffold- or graft-based strategies, have all shown promise; however, variability in study methodology, preparation techniques, and clinical outcomes continue to limit definitive recommendations. Key challenges remain, including the need for optimization and standardization of biologic formulations, patient selection criteria, and cost-effective analyses. The need for well-powered, high-quality randomized controlled trials with standardized protocols are paramount to guiding clinical decision-making. The need to optimize RCR is clear, and the interest is evident in the numerous studies in the field. Future studies should aim to establish clear guidelines for biologic augmentation, ensuring that evidence-based applications can optimize patient outcomes in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.